MA
FATE icon

MUFG Americas’s Fate Therapeutics FATE Stock Holding History

MUFG Americas’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-980
Closed -$5K – 1196
2015
Q1 		$5K Buy
980
+210
+27% +$1.04K ﹤0.01% 1018
2014
Q4 		$4K Buy
770
+340
+79% +$1.5K ﹤0.01% 1119
2014
Q3 		$2K Buy
+430
New +$2.49K ﹤0.01% 1217

Other funds holding FATE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

MUFG Americas's FATE Position: Q2 2015 in Review

MUFG Americas sold out of Fate Therapeutics (FATE) in Q2 2015, closing a stake of 980 shares — an estimated $5K sold.

MUFG Americas first reported a position in FATE in Q3 2014 and held it in 3 quarters. The position peaked at $5K in Q1 2015. 39 funds tracked by Wall St. Rank hold FATE as of Q2 2015.

  • MUFG Americas reported no remaining Fate Therapeutics position as of Q2 2015 after selling out during the quarter.
  • MUFG Americas sold 980 Fate Therapeutics shares in Q2 2015, an estimated $5K.
  • MUFG Americas first reported a position in Fate Therapeutics in Q3 2014 and held it in 3 quarters.
  • MUFG Americas's Fate Therapeutics position peaked at $5K in Q1 2015.
  • 39 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2015.

Based on MUFG Americas's 13F filing for Q2 2015, filed 13 Aug 2015.